News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeuroMetrix, Inc. (NURO) CEO Discusses Significance of WellMed Adoption of NC-stat® DPNCheck™


5/17/2012 2:39:09 PM

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer cited the recent adoption of the company’s diagnostic device, NC-stat DPNCheck, by WellMed Medical Management, www.wellmedmedicalgroup.com, as important evidence of the product’s potential in the managed care sector. Dr. Gozani detailed the significance of the WellMed agreement in an interview with CEONews.Tv at: http://www.ceonews.tv/nuro/

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES